Treatment of schizophrenia has taken so many turns, and adverse effects of the drugs still continue to remain as a hurdle in the management. Clozapine is considered to be the better promising drug in the treatment of paranoid schizophrenia with minimal side effects. Clozapine-induced agranulocytosis is one adverse event that troubles clinicians, and it requires a vigilant eye to look for the signs. In the present study, the authors discuss a case which has developed agranulocytosis in the later stages of clozapine treatment.